Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent recombinant dengue vaccine
- Development stage
- Unknown
- Lead developer
- Sun Pharmaceutical Industries
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent recombinant dengue vaccine (DSV4) is a virus-like particle (VLP)-based vaccine candidate designed to provide broad protection against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). Developed by the International Centre for Genetic Engineering and Biotechnology (ICGEB) in collaboration with Sun Pharmaceutical Industries, the vaccine utilizes a recombinant fusion protein architecture. It incorporates the envelope domain III (EDIII) from each of the four dengue serotypes, which are fused to the Hepatitis B virus surface antigen (HBsAg). The HBsAg component acts as a scaffold that drives the self-assembly of the fusion proteins into VLPs, presenting the dengue antigens in a highly organized, repetitive array to the immune system. This approach is intended to induce potent neutralizing antibodies while minimizing the risk of antibody-dependent enhancement (ADE) by excluding the highly cross-reactive prM and fusion loop epitopes found in whole-virus vaccines.
- Other names
- tetravalent EDIII-T moleculerecombinant VLP-based dengue vaccineEDIII-HBsAg VLP vaccine
02
Targets
Dengue virus serotype 4 envelope protein domain IIIHBsAg-S (Hepatitis B virus surface antigen S protein)DENV-1 E (Dengue virus serotype 1 envelope protein)Dengue virus serotype 3 envelope protein domain III (DENV3 EDIII)Dengue virus serotype 2 envelope protein domain III
Beyond the preview
Go deeper on quadrivalent recombinant dengue vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent recombinant dengue vaccine.